AccessMyLibrary provides FREE access to over 30 million articles from top publications available through your library.
Create a link to this page
Copy and paste this link tag into your Web page or blog:
YES
If incorporated appropriately, the review of economic factors by the Food and Drug Administration could help facilitate a new drug's entrance into the market.
A new drug isn't going to get far in the marketplace if managed care organizations and other payers are unwilling to cover it. And these payers want to see cost-effectiveness data. The problem is that cost-effectiveness claims are difficult and time consuming to evaluate.
If payers had an independent evaluation of cost-effectiveness from the FDA, it could make coverage decisions easier and faster--allowing cost-effective drugs a smooth path to the marketplace.
Economic data could be collected by drug companies during phase III drug trials and forwarded to the FDA as part of a new drug application (NDA).
The FDA already has some experience in evaluating cost-effectiveness claims. For example, the agency evaluates the promotional material for drugs on the market, and at least some of that review involves evaluation of cost-effectiveness claims.
It isn't a big stretch to think that the FDA could do that type of review earlier, during review of an NDA.
Source: HighBeam Research, Should the FDA consider cost-effectiveness when approving new drug...